MAY 21 3PostersMonday AfternoonMorningPO-231: 3PO-232: 3PO-233: 3PO-234: 3PO-235: 3PO-236: 3Mindfulness-Based Stress Reduction Reduces ClinicBP in PrehypertensionJoel W. Hughes†, 1 David M. Fresco, 1 Manfred vanDulmen, 1 Linda E. Carlson, 3 Richard Josephson, 4Rodney Myerscough. 2 1 Kent State University, Kent,OH, US; 2 Summa Health Center, Akron, OH, US;3 University of Calgary, Calgary, AB, CA <strong>and</strong> 4 CaseWestern Reserve University, Clevel<strong>and</strong>, OH, US.Efficacy <strong>and</strong> Safety of Azilsartan Medoxomil, aNovel Angiotensin II Receptor Blocker, in African-Americans with HypertensionW. Johnson†, 1 W. B. White, 2 D. Sica, 3 G. L., 4 M. A.Weber, 5 A. Perez, 6 C. Cao, 6 S. Kupfer, 6 E. Saunders. 11 University of Maryl<strong>and</strong> School of Medicine,Baltimore, MD, US; 2 University of ConnecticutSchool of Medicine, Farmington, CT, US; 3 VirginiaCommonwealth University Health System, Richmond,VA, US; 4 University of Chicago, Pritzker School ofMedicine, Chicago, IL, US; 5 SUNY Downstate Collegeof Medicine, New York, NY, US <strong>and</strong> 6 Takeda GlobalResearch & Development, Deerfield, IL, US.Efficacy <strong>and</strong> Onset of Antihypertensive Effects ofan Amlodipine- <strong>and</strong> Olmesartan Medoxomil-BasedTitration Regimen in Patients with Hypertension<strong>and</strong> Type 2 DiabetesDean J. Kereiakes, 1 Richard A. Sachson, 2 ChunlinQian, 3 Maninee Patel. 3 1 The Christ Hospital Heart<strong>and</strong> Vascular Center <strong>and</strong> The Carl <strong>and</strong> Edyth LindnerCenter for Research <strong>and</strong> Education at The ChristHospital, US; 2 Endocrine Associates of Dallas, US <strong>and</strong>3 Daiichi Sankyo, Inc., US.High Dose C<strong>and</strong>esartan Cilexetil in Combinationwith Hydrochlorothiazide for Second StageHypertension: CAESAR (C<strong>and</strong>esartan Effect inSecond Stage Arterial Hypertension) StudyHae-Young Lee†, 1 Dong Woon Jeon, 1 Chang-KyuPark, 1 Dong Hoon Choi, 2 Bum Ki Hong. 2 1 SeoulNational University Hospital, KR <strong>and</strong> 2 Yonseiuniversity Severance hospital, KR.Pharmacist Interventions to Enhance PatientAdherence to Antihypertensive Medication: ASystematic ReviewManuel Morgado, Liliana Castanheira, Ignácio Verde,Miguel Castelo-Branco. Health Sciences ResearchCentre, University of Beira Interior, Covilhã, PT.Effects of Nebivolol Added to OngoingAntihypertensive Therapy on Heart Rate in Patientswith Stage I-II Hypertension: Post hoc Analysis of aPhase III TrialJoel M. Neutel†, 1 David H. G. Smith. 2 1 Orange CountyResearch Center, Tustin, CA, US <strong>and</strong> 2 University ofCalifornia, Irvine, CA, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track144
Monday Morning Afternoon MAY 21 3PostersPO-237: 3PO-238: 3PO-239: 3PO-240: 3PO-241: 3Effects of an Amlodipine- <strong>and</strong> OlmesartanMedoxomil-Based Titration Regimen on 24-HourBP Profiles in Patients with Hypertension <strong>and</strong> Type2 DiabetesVenkata S. Ram, 1 Richard A. Sachson, 2 Thomas W.Littlejohn III, 3 Ali Shojaee, 4 Kathy A. Stoakes, 4 Joel M.Neutel. 5 1 University of Texas Southwestern MedicalCenter, US; 2 Endocrine Associates of Dallas, US;3 Piedmont Medical Research Associates, US; 4 DaiichiSankyo, Inc., US <strong>and</strong> 5 Orange County Research Center,US.New Angiotensin II Receptor Blocker AzilsartanMedoxomil Coadministered with ChlorthalidoneProvides Potent Blood Pressure Reduction in Stage 2HypertensionD. Sica†, 1 G. L. Bakris, 2 W. B. White, 3 M. A. Weber, 4 A.Perez, 5 C. Cao, 5 S. Kupfer. 5 1 Virginia CommonwealthUniversity Health System, Richmond, VA, US;2 University of Chicago, Pritzker School of Medicine,Chicago, IL, US; 3 University of Connecticut Schoolof Medicine, Farmington, CT, US; 4 SUNY DownstateCollege of Medicine, New York, IL, US <strong>and</strong> 5 TakedaGlobal Research & Development, Deerfield, IL, US.A Phase III Trial of Baroreflex Activation Therapyfor Resistant Hypertension: Trial Design <strong>and</strong>Baseline Characteristics in the Rheos Pivotal TrialDomenic A. Sica†, 1 George Bakris, 2 JohnBisognano, 3 Mitra Nadim, 4 Luis Sanchez. 5 1 VirginiaCommonwealth University Health System, Richmond,VA, US; 2 University of Chicago, US; 3 University ofRochester Medical Center, US; 4 University of SouthernCalifornia, US <strong>and</strong> 5 Washington University School ofMedicine, US.Morbidity <strong>and</strong> Mortality on Combination vsMonotherapy in the Systolic Hypertension in EuropeTrialLutgarde Thijs, 1 Tom Richart, 1,2 Peter W. de Leeuw, 2Tatiana Kuznetsova, 1 Tomasz Grodzicki, 3 KalinaKawecka-Jaszcz, 3 Eoin O’Brien, 4 Josep Redón, 5 WillemH. Birkenhäger, 6 Robert Fagard, 1 Jan A. Staessen†. 1,21 University of Leuven, BE; 2 Maastricht University,NL; 3 Jagiellonian University, PL; 4 University CollegeDublin, IE; 5 University of Valencia, ES <strong>and</strong> 6 ErasmusUniversity, NL.Antihypertensive Efficacy of the New AngiotensinReceptor Blocker Azilsartan Medoxomil inCombination with AmlodipineM. A. Weber†, 1 W. B. White, 2 D. Sica, 3 G. L. Bakris, 4A. Perez, 5 C. Cao, 5 S. Kupfer. 5 1 SUNY DownstateCollege of Medicine, New York, NY, US; 2 University ofConnecticut School of Medicine, Farmington, CT, US;3 Virginia Commonwealth University Health System,Richmond, VA, US; 4 University of Chicago, PritzkerSchool of Medicine, Chicago, IL, US <strong>and</strong> 5 TakedaGlobal Research & Development, Deerfield, IL, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track145
- Page 1 and 2:
American Society of Hypertension201
- Page 3 and 4:
Valturna offers bothsuperior BP eff
- Page 5 and 6:
Figure 2: Probability of Achieving
- Page 7 and 8:
potential for other drugs acting on
- Page 9 and 10:
aliskiren arms were about one-third
- Page 11 and 12:
As with other drugs that block angi
- Page 13:
American Society of Hypertension201
- Page 18:
Program Color KeyThe pages of this
- Page 21 and 22:
General InformationThis program boo
- Page 23 and 24:
General Information continuedHilton
- Page 25 and 26:
General Information continuedASH Sc
- Page 27 and 28:
General Information continuedASH Hy
- Page 29 and 30:
2010 ASH Corporate MembersBoehringe
- Page 31 and 32:
ASH Leadership2009-2010 Board of Di
- Page 33 and 34:
Special LectureMonday, May 3, 2010,
- Page 35 and 36:
Special LectureMonday, May 3, 2010,
- Page 37 and 38:
2010 Abstract Reviewers continuedEr
- Page 39 and 40:
Visit TEKTURNA at Booth 1100.and/or
- Page 41 and 42:
5.5 HyperkalemiaIncreases in serum
- Page 43 and 44:
with Pgp substrates or weak to mode
- Page 45 and 46:
ASH Program at a GlanceSaturday, Ma
- Page 47 and 48:
ASH Program at a GlanceMonday, May
- Page 49 and 50:
Poster Category PresentationPosters
- Page 51 and 52:
2010 ASH Faculty continuedJeffrey R
- Page 53 and 54:
2010 ASH Faculty continuedAndrew Wh
- Page 55 and 56:
2010American Societyof Hypertension
- Page 57 and 58:
Saturday Afternoon MAY 1PostersPost
- Page 59 and 60:
Saturday Afternoon MAY 1Sessions3:3
- Page 61 and 62:
Saturday Afternoon MAY 1Sessions3:3
- Page 63 and 64:
Sunday Morning MAY 2Satellite Sympo
- Page 65 and 66:
Sunday Morning MAY 2Sessions contin
- Page 67 and 68:
Sunday Morning MAY 2Sessions8:00 AM
- Page 69 and 70:
Sunday Morning MAY 2Sessions10:00 A
- Page 71 and 72:
Sunday Morning MAY 2Sessions10:00 A
- Page 73 and 74:
Sunday Afternoon MAY 2Sessions3:30
- Page 75 and 76:
Sunday Afternoon MAY 2Sessions3:30
- Page 77 and 78:
Sunday Afternoon MAY 2Special Sessi
- Page 79 and 80:
Sunday Evening MAY 2Sessions6:00 PM
- Page 81 and 82:
Sunday Evening MAY 2Sessions6:00 PM
- Page 83 and 84:
Monday Morning MAY 3Satellite Sympo
- Page 85 and 86:
Monday Morning MAY 3Sessions8:00 AM
- Page 87 and 88:
Monday Morning Afternoon MAY 21 3Po
- Page 89 and 90:
Monday Morning MAY 3Sessions10:00 A
- Page 91 and 92:
Monday Morning MAY 3Sessions10:00 A
- Page 93 and 94:
Monday Morning MAY 3Sessions11:45 A
- Page 95 and 96: Monday Evening May 3Satellite Sympo
- Page 97 and 98: Tuesday Morning May 48:45 AM LB-OR-
- Page 99 and 100: Tuesday Morning May 4Sessions8:00 A
- Page 101 and 102: Tuesday Morning MAY 4ASH Membership
- Page 103 and 104: Tuesday Morning MAY 4Sessions10:55
- Page 105 and 106: 2010American Societyof Hypertension
- Page 107 and 108: Saturday Afternoon MAY 1Posters3:00
- Page 109 and 110: Saturday Afternoon MAY 1PostersPO-2
- Page 111 and 112: Saturday Afternoon MAY 1PostersPO-3
- Page 113 and 114: Saturday Afternoon MAY 1PostersPO-4
- Page 115 and 116: Saturday Afternoon MAY 1PostersPO-5
- Page 117 and 118: Saturday Afternoon MAY 1PostersPO-7
- Page 119 and 120: Saturday Afternoon MAY 1PostersPO-8
- Page 121 and 122: Saturday Afternoon MAY 1PostersPO-9
- Page 123 and 124: Saturday Afternoon MAY 1PostersPO-1
- Page 125 and 126: Sunday Morning MAY 2PostersPosters
- Page 127 and 128: Sunday Morning MAY 2Posters9:00 AM
- Page 129 and 130: Sunday Morning MAY 2PostersPO-123:
- Page 131 and 132: Sunday Morning MAY 2PostersPO-137:
- Page 133 and 134: Sunday Morning MAY 2PostersPO-150:
- Page 135 and 136: Sunday Morning MAY 2PostersPO-163:
- Page 137 and 138: Sunday Morning MAY 2PostersPO-178:
- Page 139 and 140: Sunday Morning MAY 2PostersPO-193:
- Page 141 and 142: Sunday Morning MAY 2PostersPO-206:
- Page 143 and 144: Monday Morning Afternoon MAY 21 3Po
- Page 145: Monday Morning Afternoon MAY 21 3Po
- Page 149 and 150: Monday Morning Afternoon MAY 21 3Po
- Page 151 and 152: Monday Morning Afternoon MAY 21 3Po
- Page 153 and 154: Monday Morning Afternoon MAY 21 3Po
- Page 155 and 156: Monday Morning Afternoon MAY 21 3Po
- Page 157 and 158: Monday Morning Afternoon MAY 21 3Po
- Page 159 and 160: Monday Morning Afternoon MAY 21 3Po
- Page 161 and 162: Monday Morning Afternoon May 213Pos
- Page 163 and 164: Faculty Disclosure ListingGail Adle
- Page 165 and 166: Faculty Disclosure Listing continue
- Page 167 and 168: Faculty Disclosure Listing continue
- Page 169 and 170: Faculty Disclosure Listing continue
- Page 171 and 172: Faculty Disclosure Listing continue
- Page 173 and 174: you to attend thethe Innovations Th
- Page 175 and 176: 5.5 HyperkalemiaIncreases in serum
- Page 177 and 178: with Pgp substrates or weak to mode
- Page 179 and 180: Valturna (aliskiren and valsartan,
- Page 181 and 182: 4 CONTRAINDICATIONSNone.5 WARNINGS
- Page 183 and 184: een reported. In a 4-day trial of v
- Page 185 and 186: 7 DRUG INTERACTIONSNo drug interact
- Page 187 and 188: 8.5 Geriatric UseIn 8.5the Geriatri
- Page 189 and 190: 2010 ASH ExhibitorsASH Hypertension
- Page 191 and 192: ASH Hypertension Resource CenterHil
- Page 193 and 194: 2010 ASH Exhibitors continuedCVRx I
- Page 195 and 196: 2010 ASH Exhibitors continuedIntern
- Page 197 and 198:
2010 ASH Exhibitors continuedNature
- Page 199 and 200:
2010 ASH Exhibitors continuedRESPeR
- Page 201 and 202:
Author IndexAAbaunza, Ricardo, 122A
- Page 203 and 204:
Author IndexCastellano, Maurizio, 1
- Page 205 and 206:
Author IndexGuarneri, Marco, 146Guo
- Page 207 and 208:
Author IndexLekakis, John, 118, 122
- Page 209 and 210:
Author IndexPittaras, Andreas, 149P
- Page 211 and 212:
Author IndexTello, Susana, 109, 135
- Page 213 and 214:
Hilton New York Floor PlansSecond F
- Page 215 and 216:
Hilton New York Floor PlansFourth F
- Page 218:
Are You 1in 3?Get the facts. Know y